MR contrast agents, the old and the new.
暂无分享,去创建一个
[1] P. Wedeking,et al. Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.
[2] R. Semelka,et al. Contrast agents for MR imaging of the liver. , 2005, Radiologic clinics of North America.
[3] F. Lazeyras,et al. Specificity of SPIO particles for characterization of liver hemangiomas using MRI , 2003, Abdominal Imaging.
[4] M. Bellin,et al. Currently used non-specific extracellular MR contrast media , 2003, European Radiology.
[5] B. Hamm,et al. Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA. , 1999, Journal of computer assisted tomography.
[6] F. Shellock,et al. Safety of magnetic resonance imaging contrast agents , 1999, Journal of magnetic resonance imaging : JMRI.
[7] Henrik S. Thomsen,et al. The use of iodinated and gadolinium contrast media during pregnancy and lactation , 2005, European Radiology.
[8] K. Yoshikawa,et al. Safety of ProHance in special populations , 1997, European Radiology.
[9] R. Vré,et al. Invited review: biophysical properties and clinical applications of magnetic resonance imaging contrast agents. , 1995, The British journal of radiology.
[10] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[11] M. Tweedle,et al. The ProHance story: the making of a novel MRI contrast agent , 1997, European Radiology.
[12] J. Hagan,et al. Comparative chemical structure and pharmacokinetics of MRI contrast agents. , 1988 .
[13] L. Martí-Bonmatí,et al. Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis , 2003, European Radiology.
[14] E. Rummeny,et al. MnDPDP for MR imaging of the liver , 1997, Acta radiologica.
[15] M. Schreiber. The Shape of Things To Come , 1988 .
[16] D. Khayat,et al. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. , 1994, Radiology.
[17] J. Brunberg,et al. Adverse reactions to gadolinium contrast media: a review of 36 cases. , 1996, AJR. American journal of roentgenology.
[18] C. Claussen,et al. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. , 1997, Radiology.
[19] V. Lorusso,et al. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.
[20] R Weissleder,et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. , 1988, Radiology.
[21] A. Spinazzi,et al. Interim results of phase II clinical testing of gadobenate dimeglumine. , 1994, Investigative radiology.
[22] C. Chang,et al. Magnetic resonance imaging contrast agents. Design and physicochemical properties of gadodiamide. , 1993, Investigative radiology.
[23] P. Hals,et al. Biodistribution and toxicity of MR imaging contrast media , 1993, Journal of magnetic resonance imaging : JMRI.
[24] L. Vlahos,et al. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A) , 2001, Journal of magnetic resonance imaging : JMRI.
[25] M. Kirchin,et al. Safety assessment of gadobenate dimeglumine (MultiHance®): Extended clinical experience from phase I studies to post‐marketing surveillance , 2001, Journal of magnetic resonance imaging : JMRI.
[26] T. R. Lucas,et al. Safety of gadoteridol injection: U.S. clinical trial experience , 1995, Journal of magnetic resonance imaging : JMRI.
[27] H. Thomsen,et al. Oral manganese for liver and bile imaging. , 2005, Academic radiology.
[28] V. Runge,et al. Safety of approved MR contrast media for intravenous injection , 2000, Journal of magnetic resonance imaging : JMRI.
[29] T. Southon,et al. Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration , 1997, Acta radiologica.
[30] W F Bennett,et al. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging , 2000, Journal of magnetic resonance imaging : JMRI.
[31] M. Bellin,et al. Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. , 1992, Magnetic resonance imaging.
[32] D. Bluemke,et al. Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. , 2003, Radiology.
[33] A. Spinazzi,et al. Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.
[34] P. Cluzel,et al. Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences , 1999, European Radiology.
[35] J. Debatin,et al. Gadopentetate dimeglumine excretion into human breast milk during lactation. , 2000, Radiology.
[36] S. McGill,et al. MnDPDP for MR imaging of the liver , 1997, Acta radiologica.
[37] H. Thomsen,et al. Safety of MR liver specific contrast media , 2005, European Radiology.
[38] S E Seltzer,et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. , 1995, Radiology.
[39] G. Marchal,et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study. , 2000, Radiology.
[40] P. Robinson,et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. , 2004, Radiology.
[41] M. Tweedle,et al. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.